详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

A PROSPECTIVE, OPEN-LABELED, RANDOMIZED, MULTICENTER PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ERLOTINIB VS NP CHEMOTHERAPY AS ADJUVANT THERAPY IN POST RADICAL OPERATION STAGE IIIA NSCLC PATIENTS WITH EGFR 19 OR 21 EXON MUTATION (EVAN, ML28280, NCT01683175)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Tianjin Medical University Cancer Institute And Hospital/China, [2]TheThird Affiliated Hospital Of Harbin Medical University/China, [3]TheSecond People‘s Hospital O Sichuan/China, [4]Hebei Provincial TumorHospital/China, [5]The Fourth Military Medical University/China, [6]TheFirst Affiliated Hospital Of Soochow University/China, [7]ZhejiangCancer Hospital/China, [8]Beijing Cancer Hospital/China, [9]ZhongshanHospital Fudan University/China, [10]Fujian Medical University UnionHospital/China, [11]Sun Yat-Sen University Cancer/China, [12]LiaoningCancer Hospital & Institute/China, [13]The Affilated Hospital Of MedicalCollege Qingdao University/China, [14]Shenzhen People‘s Hospital/China, [15]Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University/China

出处：

ISSN：

关键词： NSCLC EGFR mutation post surgery erlotinib

语种：

WOS：

中科院分区：

出版当年[2013]版：

大类 | 2 区医学

小类 | 2 区呼吸系统 3 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2013]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 5.8 出版当年[2013版] 4.948 出版当年五年平均 4.473 出版前一年[2012版] 5.282 出版后一年[2014版]

第一作者：

第一作者机构： [1]Tianjin Medical University Cancer Institute And Hospital/China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients [2]Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China [3]The relationship between cerebrospinal fluid metastasis and gene mutations in non-small-cell lung cancer patients [4]A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China [5]Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib [6]Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. [7]High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study [8]Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405) [9]A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation [10]Specific organ metastases and survival of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation